Observational studyOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
State sequence analysis for a deeper understanding of treatment adherence patterns in fragility fracture patients.
Observational study in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared two methods to describe adherence to osteoporotic drugs after fragility fractures. While both similarly predicted refracture risk, a novel approach using sequence analysis provided a clearer picture of patient behavior, helping clinicians better understand and address adherence issues in osteoporosis care.
backgroundFragility fractures are common among individuals with osteoporosis, causing significant morbidity, mortality, and healthcare costs. Although effective pharmacological treatments exist, underdiagnosis and poor treatment adherence remain pervasive in clinical practice.
methodsIn order to select an effective methodology to describe and visually represent treatment adherence and correctly stratify patients with fragility fractures according to their adherence patterns, a conventional method using average PDC was compared to an alternative method, given by the state sequence analysis (SSA) and clustering procedure. Data on patients aged 50 or older who experienced fragility fractures between 2012 and 2017 were retrieved from healthcare utilization databases in Lombardy, Italy. Fine and Gray's model was employed to analyze the association between adherence (calculated by conventional and alternative methods) and refracture risk. Finally, the discriminatory power to predict outcomes was calculated for each approach.
resultsOut of the 8976 patients included in this observational study, four different adherence groups were considered using the conventional method (very poor, poor, intermediate, and optimal), while three clusters (non-adherence, short-term adherence, and long-term adherence) were obtained from the SSA. Compared with non-adherent patients, those with long-term adherence were found to have a significantly reduced risk of combined death and refracture with both methods. Regarding discriminatory performance, the two approaches showed similar AUC, 0.646 and 0.644 for conventional and alternative methods, respectively.
conclusionsBased on the SSA and cluster analysis, the alternative method does not significantly modify the prediction of the refracture risk but enhances the description and visualization of the adherence patterns.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.